Beam Therapeutics (BEAM) EBT Margin (2019 - 2026)
Beam Therapeutics (BEAM) posted quarterly EBT Margin of 309.75% for Q1 2026, up 115661.0% year-over-year from N/an in Q1 2025, and down 244.68% quarter-over-quarter from 214.09% in Q4 2025.
Powered by 
Analysis
Beam Therapeutics (BEAM) EBT Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported EBT Margin for 8 consecutive years, with 309.75% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 115661.0% year-over-year to 309.75%; the TTM figure through Mar 2026 stood at 42.09% (up 56751.0% YoY), while the FY2025 annual figure was 57.24%, up 53582.0% from the prior year.
- EBT Margin retreated to 309.75% in Q1 2026 per BEAM's latest filing, from 214.09% in the prior quarter.
- Across five years, EBT Margin topped out at 214.09% in Q4 2025 and bottomed at 1466.36% in Q1 2025.
- Historically, EBT Margin has averaged 654.34% across 5 years, with a median of 558.88% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin soared 336684900 bps — and 2024, when it plunged 88288 bps.
- Beam Therapeutics' EBT Margin stood at 186.4% in 2022, then surged by 124 bps to 45.59% in 2023, then tumbled by 759 bps to 300.51% in 2024, then surged by 171 bps to 214.09% in 2025, then plunged by 245 bps to 309.75% in 2026.
- Business Quant data shows BEAM's EBT Margin at 309.75% in Q1 2026, 214.09% in Q4 2025, and 1162.38% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | -24,299.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24,299.18% |
| Mar 31, 2026 | -306.72% |
| Dec 31, 2025 | 214.09% |
| Sep 30, 2025 | -1,162.38% |
| Jun 30, 2025 | -1,208.26% |
| Mar 31, 2025 | -1,464.82% |
| Dec 31, 2024 | -300.51% |
| Sep 30, 2024 | -677.47% |
| Jun 30, 2024 | -773.12% |
| Mar 31, 2024 | -1,245.38% |
| Dec 31, 2023 | 45.59% |
| Sep 30, 2023 | -558.88% |
| Jun 30, 2023 | -411.49% |
| Mar 31, 2023 | -367.51% |
| Dec 31, 2022 | -186.40% |
| Sep 30, 2022 | -516.90% |
| Jun 30, 2022 | -479.86% |
| Mar 31, 2022 | -896.36% |
| Dec 31, 2021 | -126.71% |
| Sep 30, 2021 | -3,685.19% |